Glenmark Pharmaceuticals Limited (GLENMARK)
Glenmark launches Winlevi (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris
Glenmark Specialty S.A launched Winlevi (clascoterone 10 mg/g cream) in key European markets for acne vulgaris treatment. This is Glenmark's first New Chemical Entity launch in Europe, strengthening its dermatology portfolio. The product is authorized for adults and adolescents (12 to <18 years) with facial use in adolescents. Launches include direct presence in Nordics, Central/Eastern Europe, Spain, and partnership in Portugal. Winlevi is the first topical acne therapy in 40+ years with a novel androgen-receptor inhibitor mechanism.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 GLENMARK — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add GLENMARK to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Glenmark Pharmaceuticals Limited
Important.
The summary above is generated automatically from Glenmark Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.